Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
Telli ML, Litton JK, Beck JT, Jones JM, Andersen J, Mina LA, Brig R, Danso M, Yuan Y, Symmans WF, Hopkins JF, Albacker LA, Abbattista A, Noonan K, Mata M, Laird AD, Blum JL.
Telli ML, et al. Among authors: yuan y.
Breast Cancer. 2024 Jun 13. doi: 10.1007/s12282-024-01603-4. Online ahead of print.
Breast Cancer. 2024.
PMID: 38869771